Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2000 Frontis Plaza Blvd., Suite 250 WINSTON-SALEM NC 27103 |
Tel: | N/A |
Website: | https://prokidney.com |
IR: | See website |
Key People | ||
Bruce Culleton Chief Executive Officer, Director | James Coulston Chief Financial Officer | Ulrich Ernst Executive Vice President - Technical Operations |
Joseph Stavas Senior Vice President, Head of Global Clinical Development and Interventional Procedures | Lucio Tozzi Senior Vice President - Global Clinical Operations | Darin J. Weber Chief Regulatory Officer, SVP - Global Regulatory, Quality Management & Commercial | Todd C. Girolamo Chief Legal Officer |
Business Overview |
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient's own cells isolated from the patient intended for treatment. The Company's lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient's diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient's own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant's own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD). |
Financial Overview |
For the three months ended 31 March 2024, ProKidney Corp revenues was not reported. Net loss decreased 2% to $9.5M. Lower net loss reflects Biotechnology & Medical Research segment loss decrease of 2% to $40.1M. Basic Earnings per Share excluding Extraordinary Items remained flat at -$0.16. |
Employees: | 163 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $570.13M as of Mar 31, 2024 |
Annual revenue (TTM): | $0.00M as of Mar 31, 2024 |
EBITDA (TTM): | -$146.60M as of Mar 31, 2024 |
Net annual income (TTM): | -$35.30M as of Mar 31, 2024 |
Free cash flow (TTM): | -$132.89M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 231,646,783 as of May 10, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |